Since patients receiving neoadjuvant therapy are more often diagnosed in advanced tumor stages, the influence of systemic cytostatic therapy on potentially impaired liver function, reduced physical strength, or tumor cachexia might be another possible explanation for worse outcome in those with diminished BChE. Here, BCHE is linked to neoplasm.